2024
Sex differences in comorbid pain and opioid use disorder: A scoping review
DeVito E, Ameral V, Sofuoglu M. Sex differences in comorbid pain and opioid use disorder: A scoping review. British Journal Of Clinical Pharmacology 2024, 90: 3067-3083. PMID: 39168150, PMCID: PMC11604518, DOI: 10.1111/bcp.16218.Peer-Reviewed Original ResearchOpioid use disorderChronic painTreatment of opioid use disorderChronic opioid usePost hoc analysisPersistent painClinical courseOpioid useComorbid painSex/gender differencesOpioid misuseOpioidPainUse disorderHighest prevalencePost-hocOutcome variablesDisordersTreatmentHuman subjectsBiological underpinningsPsychosocial factorsTreatment effectsSex differencesSexW82 Variation in Psychosocial Symptom Change: A Preliminary Examination of Veterans in Early Medication Treatment for Opioid Use Disorder
Wolkowicz N, Sofuoglu M, De Aquino J, MacLean R. W82 Variation in Psychosocial Symptom Change: A Preliminary Examination of Veterans in Early Medication Treatment for Opioid Use Disorder. Drug And Alcohol Dependence 2024, 260: 110700. DOI: 10.1016/j.drugalcdep.2023.110700.Peer-Reviewed Original Research
2023
Brief report: The influence of childhood trauma on the effects of delta‐9‐tetrahydrocannabinol in persons with opioid use disorder
Rogan M, Nunes J, Xie C, Sofuoglu M, Pittman B, De Aquino J. Brief report: The influence of childhood trauma on the effects of delta‐9‐tetrahydrocannabinol in persons with opioid use disorder. American Journal On Addictions 2023, 33: 343-346. PMID: 38059660, PMCID: PMC11032222, DOI: 10.1111/ajad.13504.Peer-Reviewed Original ResearchPharmacological Interventions for Impulsivity in Addictive Disorders
Schwartz E, Palmisano A, Sofuoglu M. Pharmacological Interventions for Impulsivity in Addictive Disorders. Current Addiction Reports 2023, 10: 149-165. DOI: 10.1007/s40429-023-00486-3.Peer-Reviewed Original ResearchAddictive disordersPharmacological interventionsAddiction-related outcomesRecent FindingsSeveral studiesGlutamatergic medicationsGlutamatergic systemPatient populationPharmacological treatmentTreatment approachesMedicationsDisorder outcomesDisordersFurther studiesOutcomesInterventionImpulsivityAddictive behaviorsFacets of impulsivityMore standardizationTrait impulsivityPositive signalsDopaminergicOn the Edges: The Ethics of Human Studies with Psychedelic Substances
da Costa S, Sofuoglu M. On the Edges: The Ethics of Human Studies with Psychedelic Substances. 2023, 153-171. DOI: 10.1007/978-3-031-14339-7_9.Peer-Reviewed Original ResearchClinical benefitLife-threatening conditionNovel pharmacological agentsAlcohol use disorderClinical studiesDepressive symptomsHuman studiesPharmacological agentsUse disordersMedical supervisionClassical psychedelicsTherapeutic potentialClinical researchPsychoactive effectsPsychedelic substancesControlled Substances ActHuman researchAccepted medical useConsistent evidenceDisordersPsychedelicsSubstances ActSchedule IMedical useRecreational use
2022
Cocaine Use Disorder (CUD): Current Clinical Perspectives
Schwartz EKC, Wolkowicz NR, De Aquino JP, MacLean RR, Sofuoglu M. Cocaine Use Disorder (CUD): Current Clinical Perspectives. Substance Abuse And Rehabilitation 2022, 13: 25-46. PMID: 36093428, PMCID: PMC9451050, DOI: 10.2147/sar.s337338.Peer-Reviewed Original ResearchCocaine use disorderCo-occurring disordersUse disordersCommon co-occurring disordersCurrent clinical perspectivesSubstance use disordersCognitive behavioral therapyMedication treatmentPharmacological treatmentRisk factorsCurrent treatmentDevastating disorderLarger sample sizeTreatment planChronic effectsCocaine useBehavioral treatmentClinical perspectiveBehavioral interventionsDisordersTreatmentFuture studiesMost individualsIndividualsSample size
2019
Randomized placebo-controlled trial of galantamine in individuals with cocaine use disorder
DeVito EE, Carroll KM, Babuscio T, Nich C, Sofuoglu M. Randomized placebo-controlled trial of galantamine in individuals with cocaine use disorder. Journal Of Substance Use And Addiction Treatment 2019, 107: 29-37. PMID: 31757262, PMCID: PMC6918721, DOI: 10.1016/j.jsat.2019.08.009.Peer-Reviewed Original ResearchConceptsCocaine use disorderSignificant treatment group differencesUse disordersEfficacy of galantamineTreatment-seeking cocaine usersCurrent cocaine use disordersGroup differencesCocaine use outcomesSample of individualsTreatment group differencesComorbid opioid use disorderMethadone-maintained individualsMemory capacityAbstinent individualsCocaine useCognitive improvementCognitive outcomesCocaine use reductionCognitive functionUse outcomesCocaine usersGalantamine groupIndividualsDisordersInitial promisePharmacotherapies for PTSD and Substance Use Disorders
Kachadourian L, Jensen K, Sofuoglu M, Petrakis I. Pharmacotherapies for PTSD and Substance Use Disorders. 2019, 239-259. DOI: 10.4324/9781315442648-13.ChaptersOpioid use disorderAlcohol use disorderPosttraumatic stress disorderUse disordersPTSD/SUDPharmacological treatmentComorbid posttraumatic stress disorderUse of pharmacotherapySubstance use disordersEffectiveness of foodIntramuscular naltrexoneLabel medicationsEpidemiological studiesMedication developmentDrug AdministrationPharmacotherapyStress disorderAvailable evidenceDisordersNew targetsNaltrexoneTreatmentBiological mechanismsSpecific substancesSUD
2018
Stimulants and Mood Disorders
MacLean R, Sofuoglu M. Stimulants and Mood Disorders. Current Addiction Reports 2018, 5: 323-329. DOI: 10.1007/s40429-018-0212-0.Peer-Reviewed Original ResearchStimulant use disorderMood disordersUse disordersSUD comorbidityClinical trialsComorbid substance use disorderRecent FindingsEpidemiological studiesCo-occurring mood disordersSubstance use disordersMethamphetamine use disorderMajority of trialsClinical outcomesPharmacological treatmentTreatment responseNeurobiological mechanismsDisordersMultiple studiesTrialsComorbiditiesPatientsDiagnosisMoodTreatmentPurposeToEpidemiology
2017
Neurocognitive Function as a Treatment Target for Tobacco Use Disorder
Robinson C, Waters A, Kang N, Sofuoglu M. Neurocognitive Function as a Treatment Target for Tobacco Use Disorder. Current Behavioral Neuroscience Reports 2017, 4: 10-20. DOI: 10.1007/s40473-017-0105-x.Peer-Reviewed Original ResearchCognitive processesTobacco use disorderAutomatic cognitive processesExecutive cognitive processesApproach-avoidance taskTranscranial direct current stimulationUse disordersDirect current stimulationExecutive processesAutomatic cognitionCognitive improvementCognitive functionNeurocognitive functionCurrent stimulationDistinct literaturesFuture researchTreatment targetsCognitionFurther researchDisordersRecent FindingsThereResearchBeneficial effectsTaskSmall samples